The shares of Histogen Inc. (HSTO) rose 5.87% to $0.8799 in Friday’s after-hours trading. At the end of the regular trading session, Histogen stock closed at $0.83, down -1.01%. The volume of shares traded on HSTO stock was 0.44 million, which is below the average daily trading volume of 1.89 million shares for the past 50 days.

In the last five days, HSTO stock has declined -14.27%, but over the past month, they have lost -17.71%. The HSTO stock price has fallen by -19.31% over the past three months and is down by -72.11 percent year-to-date. Due to the HSTO stock’s rise in the absence of current news, developments have been observed that lend clarity to HSTO’s current situation.

Have things been going well at HSTO lately?

In addition to developing potential first-in-class restorative therapeutics, Histogen engages the body’s natural mechanisms for repairing and maintaining healthy biological function. Hypoxia-induced multipotent cells produce cell conditioned media and extracellular matrix materials for HSTO’s innovative technology platform. With its proprietary, reproducible manufacturing process, HSTO offers tailored solutions across a wide range of therapeutic indications, including joint cartilage regeneration, spinal disk repair, and dermal rejuvenation.

Histogen recently announced that it will begin testing its HST 003 in Phase 1/2 clinical trials.

• Human extracellular matrix (hECM:HST 0003) was implanted within microfracture interstices or cartilage defects in the knee in order to restore hyaline cartilage in conjunction with a microfracture procedure in the HSTO trial.
• Walter Reed Medical Center in Bethesda, MD, The Steadman Clinic in Vail, CO, and OasisMD in San Diego, CA, are participating in HSTO’s trial.
• By using a novel scaffold that stimulates the body’s own stem cells, HSTO’s hECM aims to regenerate hyaline cartilage for the treatment of articular cartilage defects.
• A number of preclinical studies have demonstrated that HST 003 regenerates mature cartilage and well-vascularized bone, which suggests great therapeutic potential in sports medicine, spinal disc repair, orthopedic, and dental fields.
• HSTO’s double-blind placebo-controlled trial aims to evaluate whether hECM can regenerate hyaline cartilage in combination with microfracture in microfracture interstices and cartilage defects in the knee.
• Safety assessments, MRI scans to check for cartilage regeneration, and Knee Injury and Osteoarthritis Outcome Score (KOOS) and International Knee Documentation Committee (IKDC) scores will serve as primary and secondary endpoints, respectively.

The trial will help HSTO grow in what ways?

A significant milestone has been achieved for Histogen (HSTO) with the initiation of the HST 003 clinical trial. With the trial, HSTO will continue to work on developing top-of-the-line orthopedic therapeutics based on its regenerative medicine platform technology.